Currently Enrolling Trials
Alphagan has been approved for the treatment of open-angle glaucoma and ocular hypertension.
Mechanism of Action
Alphagan is a selective alpha-2 agonist, which significantly lowers intraocular pressure with minimal effects on cardiovascular and pulmonary parameters. Its unique dual mechanism of action lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow.
Glaucoma, an eye disease commonly characterized by excessive intraocular pressure, is a leading cause of blindness in the world.